J&J to Pay $2.2B Upfront for Ollin and Its Phase 3 Eye Drug

Johnson & Johnson has agreed to buy Ollin Biosciences, a clinical-stage developer of eye disease drugs, for $2.2 billion upfront. The deal gives J&J OLN324, a phase 3 antibody for retinal diseases including wet age-related macular degeneration (AMD) and diabetic macular edema. J&J announced the agreement from New Brunswick, New Jersey, on November 16, 2026.
What happened
J&J will pay $2.2 billion upfront for Ollin. Up to approximately $1.125 billion more could follow if regulatory and commercial milestones are met, the company said.
J&J also plans a separate funding agreement with Blackstone Life Sciences. Under it, Blackstone will pay J&J a total of $750 million over multiple years. That money is meant to fully fund the phase 3 development of OLN324. In return, Blackstone can earn regulatory and sales milestone payments plus single-digit royalties. The Blackstone agreement only takes effect if the acquisition closes.
J&J expects the purchase to close before the end of 2026. Closing depends on regulatory approvals and the usual conditions. J&J said it will share how it plans to account for the deal on or before closing.
Why it matters
OLN324 is a bispecific antibody. It is built to hit two pathways tied to retinal disease: vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2). J&J describes it as a small protein format, called a minibody, with high Ang2 potency. The company says that design could give better control of fluid in the retina.
Wet AMD and diabetic macular edema together affect more than 40 million people worldwide, according to J&J. Both are leading causes of vision loss.
Kip Connor, who leads J&J's ophthalmology disease area, said the drug may offer stronger and longer-lasting disease control. He also said it may allow more time between treatments. The release did not include trial figures, so those claims are the company's view for now.
The deal structure is also worth noting. An outside investor, Blackstone, is set to fully fund the late-stage trials, in exchange for milestones and royalties.
What it means for people in the industry
J&J did not say anything about jobs, sites or Ollin's staff, or where Ollin is based. The next steps to watch are the deal closing by year end, the accounting details, and phase 3 progress for OLN324.
The purchase builds on what J&J calls its long-standing presence in vision care.
See open pharma jobs in the US and Canada
Sources
Check Your Supplement Interactions
Use our AI-powered checker to analyze supplement safety and interactions.
Open Interaction Checker →Comments (0)
This article is for informational purposes only and does not constitute medical or investment advice. It was written with AI assistance from the sources listed above. Check the original sources before relying on any detail.